Literature DB >> 17324745

Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).

Timo P Hiltunen1, Timo Suonsyrjä, Tuula Hannila-Handelberg, Kristian J Paavonen, Helena E Miettinen, Timo Strandberg, Ilkka Tikkanen, Reijo Tilvis, Pertti J Pentikäinen, Juha Virolainen, Kimmo Kontula.   

Abstract

BACKGROUND: Only a minority of hypertensive individuals is adequately controlled for their hypertension, partially because reliable predictors for efficient antihypertensive drug therapy are lacking.
METHODS: In a prospective, randomized, double-blind, cross-over, placebo-controlled study (The GENRES Study), 208 moderately hypertensive Finnish men (aged 35 to 60 years) were treated for 4 weeks with antihypertensive drugs from four different classes: amlodipine (5 mg), bisoprolol (5 mg), hydrochlorothiazide (25 mg), or losartan (50 mg) daily. Each individual received each of the four monotherapies in a randomized order. Four-week placebo periods were included before and between drug treatment periods. Antihypertensive responses were assessed with 24-h ambulatory and office measurements and analyzed according to age, body mass index, triceps skin fold thickness, waist-to-hip ratio, duration of hypertension, number of previous antihypertensive drugs, number of affected parents, and blood pressure (BP) levels, and profiles during placebo periods.
RESULTS: The median BP responses in 24-h ambulatory recordings (systolic/diastolic) were 11/8 mm Hg for bisoprolol, 9/6 mm Hg for losartan, 7/5 mm Hg for amlodipine, and 5/2 mm Hg for hydrochlorothiazide. The highest pairwise within-subject correlations in BP responses were seen for the combinations of bisoprolol-losartan and amlodipine-hydrochlorothiazide. The BP responses to bisoprolol and losartan did not vary according to the variables. Amlodipine and hydrochlorothiazide responses were positively correlated with age, placebo BP level, and lower night-time dipping on placebo.
CONCLUSIONS: Baseline clinical and BP parameters may be used to predict the efficacy of antihypertensive therapies. The GENRES Study material should provide an excellent platform for future pharmacogenetic analyses of antihypertensive drug responsiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324745     DOI: 10.1016/j.amjhyper.2006.09.006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  21 in total

1.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

2.  PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.

Authors:  Yan Gong; Caitrin W McDonough; Amber L Beitelshees; Nihal El Rouby; Timo P Hiltunen; Jeffrey R O'Connell; Sandosh Padmanabhan; Taimour Y Langaee; Karen Hall; Siegfried O F Schmidt; Robert W Curry; John G Gums; Kati M Donner; Kimmo K Kontula; Kent R Bailey; Eric Boerwinkle; Atsushi Takahashi; Toshihiro Tanaka; Michiaki Kubo; Arlene B Chapman; Stephen T Turner; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Hypertens       Date:  2015-11       Impact factor: 4.844

Review 3.  Advancing management of hypertension through pharmacogenomics.

Authors:  Julie A Johnson
Journal:  Ann Med       Date:  2012-06       Impact factor: 4.709

4.  TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.

Authors:  Martina Chittani; Roberta Zaninello; Chiara Lanzani; Francesca Frau; Maria F Ortu; Erika Salvi; Giovanni Fresu; Lorena Citterio; Daniele Braga; Daniela A Piras; Simona Delli Carpini; Dinesh Velayutham; Marco Simonini; Giuseppe Argiolas; Simona Pozzoli; Chiara Troffa; Valeria Glorioso; Kimmo K Kontula; Timo P Hiltunen; Kati M Donner; Stephen T Turner; Eric Boerwinkle; Arlene B Chapman; Sandosh Padmanabhan; Anna F Dominiczak; Olle Melander; Julie A Johnson; Rhonda M Cooper-Dehoff; Yan Gong; Natalia V Rivera; Gianluigi Condorelli; Bruno Trimarco; Paolo Manunta; Daniele Cusi; Nicola Glorioso; Cristina Barlassina
Journal:  J Hypertens       Date:  2015-06       Impact factor: 4.844

5.  Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction.

Authors:  Daniel H Katz; Rahul C Deo; Frank G Aguilar; Senthil Selvaraj; Eva E Martinez; Lauren Beussink-Nelson; Kwang-Youn A Kim; Jie Peng; Marguerite R Irvin; Hemant Tiwari; D C Rao; Donna K Arnett; Sanjiv J Shah
Journal:  J Cardiovasc Transl Res       Date:  2017-03-03       Impact factor: 4.132

Review 6.  Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.

Authors:  Erika Salvi; Zhiying Wang; Federica Rizzi; Yan Gong; Caitrin W McDonough; Sandosh Padmanabhan; Timo P Hiltunen; Chiara Lanzani; Roberta Zaninello; Martina Chittani; Kent R Bailey; Antti-Pekka Sarin; Matteo Barcella; Olle Melander; Arlene B Chapman; Paolo Manunta; Kimmo K Kontula; Nicola Glorioso; Daniele Cusi; Anna F Dominiczak; Julie A Johnson; Cristina Barlassina; Eric Boerwinkle; Rhonda M Cooper-DeHoff; Stephen T Turner
Journal:  Hypertension       Date:  2016-10-31       Impact factor: 10.190

7.  Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.

Authors:  F Gueyffier; F Subtil; T Bejan-Angoulvant; Y Zerbib; J P Baguet; J M Boivin; A Mercier; G Leftheriotis; J P Gagnol; J P Fauvel; C Giraud; G Bricca; D Maucort-Boulch; S Erpeldinger
Journal:  J Hum Hypertens       Date:  2014-04-17       Impact factor: 3.012

8.  Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.

Authors:  Stephen T Turner; Eric Boerwinkle; Jeffrey R O'Connell; Kent R Bailey; Yan Gong; Arlene B Chapman; Caitrin W McDonough; Amber L Beitelshees; Gary L Schwartz; John G Gums; Sandosh Padmanabhan; Timo P Hiltunen; Lorena Citterio; Kati M Donner; Thomas Hedner; Chiara Lanzani; Olle Melander; Janna Saarela; Samuli Ripatti; Björn Wahlstrand; Paolo Manunta; Kimmo Kontula; Anna F Dominiczak; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

9.  Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension.

Authors:  Ranganath Muniyappa; Gail Hall; Terrie L Kolodziej; Rajaram J Karne; Sonja K Crandon; Michael J Quon
Journal:  Am J Clin Nutr       Date:  2008-12       Impact factor: 7.045

10.  Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.

Authors:  Michael T Eadon; Sri H Kanuri; Arlene B Chapman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.